Antioxidants Targeting Mitochondrial Oxidative Stress: Promising Neuroprotectants for Epilepsy

Nan Yang1,2,3,4, Qi-Wen Guan1,2,3,4, Fang-Hui Chen5

  • 1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, China.

Insights

Mitochondrial oxidative stress contributes to epilepsy. Antioxidants targeting mitochondria show neuroprotective effects by modulating cell death pathways, offering hope for improved epilepsy prognosis.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Cell Biology

Background:

  • Mitochondria generate reactive oxygen species (ROS), making them susceptible to oxidative stress.
  • Mitochondrial damage contributes to cell death and neurological disorders like epilepsy.
  • Excessive ROS in epilepsy pathophysiology highlights the need for antioxidant interventions.

Purpose of the Study:

  • To review the role of mitochondrial oxidative stress in epilepsy.
  • To discuss the neuroprotective potential of various antioxidants targeting mitochondria in epilepsy.
  • To explore the mechanisms of antioxidant action, including modulation of cell death pathways.

Main Methods:

  • Literature review on mitochondrial oxidative stress and epilepsy.
  • Analysis of studies on antioxidant efficacy in epilepsy models.
  • Examination of evidence for antioxidant modulation of autophagy, apoptosis, and ferroptosis.

Main Results:

  • Mitochondrial oxidative stress is implicated in epilepsy development and progression.
  • Targeted antioxidants, including mitochondria-specific agents, polyphenols, vitamins, thiols, and Nrf2 activators, demonstrate neuroprotective effects.
  • Antioxidants may exert neuroprotection by influencing interactions between autophagy, apoptosis, and ferroptosis.

Conclusions:

  • Antioxidants targeting mitochondrial oxidative stress are promising for epilepsy treatment.
  • Modulating cell death pathways like autophagy-apoptosis and autophagy-ferroptosis is a key mechanism for antioxidant neuroprotection in epilepsy.
  • Further research into these mechanisms can optimize antioxidant therapies for epilepsy.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
17.3K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
713
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
632
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
916
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
455
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
984